2025 · 2nd Quarter (Apr 1 - June 30)

AMGEN

Filed by THE MCMANUS GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 21, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: THE MCMANUS GROUP
Client: AMGEN
Filing UUID: a04d4bb1-e057-4f13-a752-d38f24e31dcf
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model

Literal federal measure citations: H.R. 1492

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.